John Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
John Williams has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Simon de Lusignan
Affiliations Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, Royal College of General Practitioners, London, United Kingdom
22 shared publications - Frederick David Richard Hobbs
University of Oxford
13 shared publications - Harshana Liyanage
UK Health Security Agency
13 shared publications - Julian Sherlock
Nuffield Department of Primary Care Health Sciences University of Oxford Oxford United Kingdom
13 shared publications - Filipa Ferreira
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
12 shared publications - Cecilia Okusi
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
11 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e002923
Disparities in the care and direct-acting oral anticoagulant (DOAC) management in atrial fibrillation (AF) and chronic kidney disease (CKD) in English primary care between 2018 and 2022: primary care sentinel network database study
Background: In England, most prescribing of direct-acting oral anticoagulants (DOACs) for patients with chronic kidney disease (CKD) and atrial fibrillation (AF) takes place in primary care. The 2024 European Society of Cardiology guidelines introduced the AF-CARE ((C) comorbidities and risk factors; (A) avoid stroke and thromboembolism by appropriate prescription of oral anticoagulants; (R) rate and rhythm control; (E) evaluation and reassessment should be individualised for every patient, with a dynamic approach) framework to address this. Objective: To describe any health disparities in CKD and AF, including anticoagulation management and correct dosing of DOACs. Methods: Using English primary care sentinel network data from 2018 to 2022, demographics of AF and CKD including anticoagulation and appropriate DOAC dosing according to creatinine clearance and other factors were assessed. The study also examined disparities in CKD and AF in relation to socioeconomic status and ethnicity. We defined socioeconomic status by Index of Multiple Deprivation (IMD), a weighted composite index combining information from the domains of deprivation including income. Results: Of 10 513 950 people registered with general practices in the sentinel network, 2.9% (n=304 678) were aged ≥18 years with a diagnosis of AF. The prevalence of CKD in AF was 26.0% (n=79 210) and 63.3% of people eligible for anticoagulation were prescribed a DOAC. Among the 54 897 people with AF and CKD 3 or 4, greater likelihood of DOAC prescribing was associated with higher socioeconomic status. Socioeconomic disparities in anticoagulation increased through the 5 years. No association was identified between ethnicity and likelihood of being anticoagulated. In terms of correct dosing, there was no association with socioeconomic status. Overdosing was more frequent than underdosing. Incorrect dosing was associated with male sex (OR 0.80 (95% CI 0.74, 0.86)), dementia (OR 0.94 (0.83, 1.07)) and frailty (OR 0.42 (0.37, 0.48)). Conclusions: People in the most deprived IMD quintile were least likely to be anticoagulated. Incorrect DOAC dosing was associated with male sex, increasing frailty and dementia. Socioeconomic and health disparities are apparent in anticoagulation prescribing and should be addressed in line with the AF-CARE framework.
- 1 January 2025
- Published by BMJ in Open Heart
- Vol. 12 (1) , e002923
Open AccessDisparities in the care and direct-acting oral anticoagulant (DOAC) management in atrial fibrillation (AF) and chronic kidney disease (CKD) in English primary care between 2018 and 2022: primary care sentinel network database study
Background: In England, most prescribing of direct-acting oral anticoagulants (DOACs) for patients with chronic kidney disease (CKD) and atrial fibrillation (AF) takes place in primary care. The 2024 European Society of Cardiology guidelines introduced the AF-CARE ((C) comorbidities and risk factors; (A) avoid stroke and thromboembolism by appropriate prescription of oral anticoagulants; (R) rate and rhythm control; (E) evaluation and reassessment should be individualised for every patient, with a dynamic approach) framework to address this. Objective: To describe any health disparities in CKD and AF, including anticoagulation management and correct dosing of DOACs. Methods: Using English primary care sentinel network data from 2018 to 2022, demographics of AF and CKD including anticoagulation and appropriate DOAC dosing according to creatinine clearance and other factors were assessed. The study also examined disparities in CKD and AF in relation to socioeconomic status and ethnicity. We defined socioeconomic status by Index of Multiple Deprivation (IMD), a weighted composite index combining information from the domains of deprivation including income. Results: Of 10 513 950 people registered with general practices in the sentinel network, 2.9% (n=304 678) were aged ≥18 years with a diagnosis of AF. The prevalence of CKD in AF was 26.0% (n=79 210) and 63.3% of people eligible for anticoagulation were prescribed a DOAC. Among the 54 897 people with AF and CKD 3 or 4, greater likelihood of DOAC prescribing was associated with higher socioeconomic status. Socioeconomic disparities in anticoagulation increased through the 5 years. No association was identified between ethnicity and likelihood of being anticoagulated. In terms of correct dosing, there was no association with socioeconomic status. Overdosing was more frequent than underdosing. Incorrect dosing was associated with male sex (OR 0.80 (95% CI 0.74, 0.86)), dementia (OR 0.94 (0.83, 1.07)) and frailty (OR 0.42 (0.37, 0.48)). Conclusions: People in the most deprived IMD quintile were least likely to be anticoagulated. Incorrect DOAC dosing was associated with male sex, increasing frailty and dementia. Socioeconomic and health disparities are apparent in anticoagulation prescribing and should be addressed in line with the AF-CARE framework.
- Open Access
- 12 August 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (4) , 315-327
COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study
- 12 August 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (4) , 315-327
Open AccessCOVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study
- Open Access
- 18 July 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 32, 100681
Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort
- 18 July 2023
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 32, 100681
Open AccessThrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort
- Open Access
- 1 February 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (731) , e435-e442
Development of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study
Background: People with multiple health conditions are more likely to have poorer health outcomes and greater care and service needs; a reliable measure of multimorbidity would inform management strategies and resource allocation.Aim: To develop and validate a modified version of the Cambridge Multimorbidity Score in an extended age range, using clinical terms that are routinely used in electronic health records across the world (Systematized Nomenclature of Medicine — Clinical Terms, SNOMED CT).Design and setting: Observational study using diagnosis and prescriptions data from an English primary care sentinel surveillance network between 2014 and 2019.Method: In this study new variables describing 37 health conditions were curated and the associations modelled between these and 1-year mortality risk using the Cox proportional hazard model in a development dataset (n= 300 000). Two simplified models were then developed — a 20-condition model as per the original Cambridge Multimorbidity Score and a variable reduction model using backward elimination with Akaike information criterion as the stopping criterion. The results were compared and validated for 1-year mortality in a synchronous validation dataset (n= 150 000), and for 1-year and 5-year mortality in an asynchronous validation dataset (n= 150 000).Results: The final variable reduction model retained 21 conditions, and the conditions mostly overlapped with those in the 20-condition model. The model performed similarly to the 37- and 20-condition models, showing high discrimination and good calibration following recalibration.Conclusion: This modified version of the Cambridge Multimorbidity Score allows reliable estimation using clinical terms that can be applied internationally across multiple healthcare settings.
- 1 February 2023
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (731) , e435-e442
Open AccessDevelopment of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study
Background: People with multiple health conditions are more likely to have poorer health outcomes and greater care and service needs; a reliable measure of multimorbidity would inform management strategies and resource allocation.Aim: To develop and validate a modified version of the Cambridge Multimorbidity Score in an extended age range, using clinical terms that are routinely used in electronic health records across the world (Systematized Nomenclature of Medicine — Clinical Terms, SNOMED CT).Design and setting: Observational study using diagnosis and prescriptions data from an English primary care sentinel surveillance network between 2014 and 2019.Method: In this study new variables describing 37 health conditions were curated and the associations modelled between these and 1-year mortality risk using the Cox proportional hazard model in a development dataset (n= 300 000). Two simplified models were then developed — a 20-condition model as per the original Cambridge Multimorbidity Score and a variable reduction model using backward elimination with Akaike information criterion as the stopping criterion. The results were compared and validated for 1-year mortality in a synchronous validation dataset (n= 150 000), and for 1-year and 5-year mortality in an asynchronous validation dataset (n= 150 000).Results: The final variable reduction model retained 21 conditions, and the conditions mostly overlapped with those in the 20-condition model. The model performed similarly to the 37- and 20-condition models, showing high discrimination and good calibration following recalibration.Conclusion: This modified version of the Cambridge Multimorbidity Score allows reliable estimation using clinical terms that can be applied internationally across multiple healthcare settings.
- Open Access
- 19 January 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (3) , 2200195-32
Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study
Background: Post-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 vaccines. Aim: To estimate the incidence of AEIs presenting to primary care following COVID-19 vaccination in England, and report safety profile differences between vaccine brands. Methods: We used a self-controlled case series design to estimate relative incidence (RI) of AEIs reported to the national sentinel network, the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. We compared AEIs (overall and by clinical category) 7 days pre- and post-vaccination to background levels between 1 October 2020 and 12 September 2021. Results: Within 7,952,861 records, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs, 4.85% within 7 days post-vaccination. Overall, medically attended AEIs decreased post-vaccination against background levels. There was a 3–7% decrease in incidence within 7 days after both doses of Comirnaty (RI: 0.93; 95% CI: 0.91–0.94 and RI: 0.96; 95% CI: 0.94–0.98, respectively) and Vaxzevria (RI: 0.97; 95% CI: 0.95–0.98). A 20% increase was observed after one dose of Spikevax (RI: 1.20; 95% CI: 1.00–1.44). Fewer AEIs were reported as age increased. Types of AEIs, e.g. increased neurological and psychiatric conditions, varied between brands following two doses of Comirnaty (RI: 1.41; 95% CI: 1.28–1.56) and Vaxzevria (RI: 1.07; 95% CI: 0.97–1.78). Conclusion: COVID-19 vaccines are associated with a small decrease in medically attended AEI incidence. Sentinel networks could routinely report common AEI rates, contributing to reporting vaccine safety.
- 19 January 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (3) , 2200195-32
Open AccessAdverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study
Background: Post-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 vaccines. Aim: To estimate the incidence of AEIs presenting to primary care following COVID-19 vaccination in England, and report safety profile differences between vaccine brands. Methods: We used a self-controlled case series design to estimate relative incidence (RI) of AEIs reported to the national sentinel network, the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. We compared AEIs (overall and by clinical category) 7 days pre- and post-vaccination to background levels between 1 October 2020 and 12 September 2021. Results: Within 7,952,861 records, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs, 4.85% within 7 days post-vaccination. Overall, medically attended AEIs decreased post-vaccination against background levels. There was a 3–7% decrease in incidence within 7 days after both doses of Comirnaty (RI: 0.93; 95% CI: 0.91–0.94 and RI: 0.96; 95% CI: 0.94–0.98, respectively) and Vaxzevria (RI: 0.97; 95% CI: 0.95–0.98). A 20% increase was observed after one dose of Spikevax (RI: 1.20; 95% CI: 1.00–1.44). Fewer AEIs were reported as age increased. Types of AEIs, e.g. increased neurological and psychiatric conditions, varied between brands following two doses of Comirnaty (RI: 1.41; 95% CI: 1.28–1.56) and Vaxzevria (RI: 1.07; 95% CI: 0.97–1.78). Conclusion: COVID-19 vaccines are associated with a small decrease in medically attended AEI incidence. Sentinel networks could routinely report common AEI rates, contributing to reporting vaccine safety.
- Open Access
- 19 December 2022
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (12) , e39141
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary
Background: The Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) is one of Europe’s oldest sentinel systems, working with the UK Health Security Agency (UKHSA) and its predecessor bodies for 55 years. Its surveillance report now runs twice weekly, supplemented by online observatories. In addition to conducting sentinel surveillance from a nationally representative group of practices, the RSC is now also providing data for syndromic surveillance. Objective: The aim of this study was to describe the cohort profile at the start of the 2021-2022 surveillance season and recent changes to our surveillance practice. Methods: The RSC’s pseudonymized primary care data, linked to hospital and other data, are held in the Oxford-RCGP Clinical Informatics Digital Hub, a Trusted Research Environment. We describe the RSC’s cohort profile as of September 2021, divided into a Primary Care Sentinel Cohort (PCSC)—collecting virological and serological specimens—and a larger group of syndromic surveillance general practices (SSGPs). We report changes to our sampling strategy that brings the RSC into alignment with European Centre for Disease Control guidance and then compare our cohort’s sociodemographic characteristics with Office for National Statistics data. We further describe influenza and COVID-19 vaccine coverage for the 2020-2021 season (week 40 of 2020 to week 39 of 2021), with the latter differentiated by vaccine brand. Finally, we report COVID-19–related outcomes in terms of hospitalization, intensive care unit (ICU) admission, and death. Results: As a response to COVID-19, the RSC grew from just over 500 PCSC practices in 2019 to 1879 practices in 2021 (PCSC, n=938; SSGP, n=1203). This represents 28.6% of English general practices and 30.59% (17,299,780/56,550,136) of the population. In the reporting period, the PCSC collected >8000 virology and >23,000 serology samples. The RSC population was broadly representative of the national population in terms of age, gender, ethnicity, National Health Service Region, socioeconomic status, obesity, and smoking habit. The RSC captured vaccine coverage data for influenza (n=5.4 million) and COVID-19, reporting dose one (n=11.9 million), two (n=11 million), and three (n=0.4 million) for the latter as well as brand-specific uptake data (AstraZeneca vaccine, n=11.6 million; Pfizer, n=10.8 million; and Moderna, n=0.7 million). The median (IQR) number of COVID-19 hospitalizations and ICU admissions was 1181 (559-1559) and 115 (50-174) per week, respectively. Conclusions: The RSC is broadly representative of the national population; its PCSC is geographically representative and its SSGPs are newly supporting UKHSA syndromic surveillance efforts. The network captures vaccine coverage and has expanded from reporting primary care attendances to providing data on onward hospital outcomes and deaths. The challenge remains to increase virological and serological sampling to monitor the effectiveness and waning of all vaccines available in a timely manner.
- 19 December 2022
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 8 (12) , e39141
Open AccessRepresentativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary
Background: The Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) is one of Europe’s oldest sentinel systems, working with the UK Health Security Agency (UKHSA) and its predecessor bodies for 55 years. Its surveillance report now runs twice weekly, supplemented by online observatories. In addition to conducting sentinel surveillance from a nationally representative group of practices, the RSC is now also providing data for syndromic surveillance. Objective: The aim of this study was to describe the cohort profile at the start of the 2021-2022 surveillance season and recent changes to our surveillance practice. Methods: The RSC’s pseudonymized primary care data, linked to hospital and other data, are held in the Oxford-RCGP Clinical Informatics Digital Hub, a Trusted Research Environment. We describe the RSC’s cohort profile as of September 2021, divided into a Primary Care Sentinel Cohort (PCSC)—collecting virological and serological specimens—and a larger group of syndromic surveillance general practices (SSGPs). We report changes to our sampling strategy that brings the RSC into alignment with European Centre for Disease Control guidance and then compare our cohort’s sociodemographic characteristics with Office for National Statistics data. We further describe influenza and COVID-19 vaccine coverage for the 2020-2021 season (week 40 of 2020 to week 39 of 2021), with the latter differentiated by vaccine brand. Finally, we report COVID-19–related outcomes in terms of hospitalization, intensive care unit (ICU) admission, and death. Results: As a response to COVID-19, the RSC grew from just over 500 PCSC practices in 2019 to 1879 practices in 2021 (PCSC, n=938; SSGP, n=1203). This represents 28.6% of English general practices and 30.59% (17,299,780/56,550,136) of the population. In the reporting period, the PCSC collected >8000 virology and >23,000 serology samples. The RSC population was broadly representative of the national population in terms of age, gender, ethnicity, National Health Service Region, socioeconomic status, obesity, and smoking habit. The RSC captured vaccine coverage data for influenza (n=5.4 million) and COVID-19, reporting dose one (n=11.9 million), two (n=11 million), and three (n=0.4 million) for the latter as well as brand-specific uptake data (AstraZeneca vaccine, n=11.6 million; Pfizer, n=10.8 million; and Moderna, n=0.7 million). The median (IQR) number of COVID-19 hospitalizations and ICU admissions was 1181 (559-1559) and 115 (50-174) per week, respectively. Conclusions: The RSC is broadly representative of the national population; its PCSC is geographically representative and its SSGPs are newly supporting UKHSA syndromic surveillance efforts. The network captures vaccine coverage and has expanded from reporting primary care attendances to providing data on onward hospital outcomes and deaths. The challenge remains to increase virological and serological sampling to monitor the effectiveness and waning of all vaccines available in a timely manner.
- Open Access
- 7 October 2022
- Published by JMIR Publications Inc. in JMIR Preprints
A novel ontological approach reveals underuse and variation in the use of physical activity interventions to address CVD risk factors in England primary care: Observational study (Preprint)
BACKGROUND In 2019, cardiovascular disease (CVD) accounted for 14% of total disability-adjusted life years and 30% of all deaths in England. Fast forwarding to 2020, many healthcare systems were on the verge of being overwhelmed by COVID-19, which disproportionately manifested as severe cases in populations affected by non-communicable diseases, most of which are CVD-risk factors. Physical activity interventions (PA-I) have been shown to play an important role in helping to address CVD risk factors and primary care has an essential role to play in supporting patients to improve their health through these types of interventions. OBJECTIVE In this manuscript, we explore the use of PA-I in primary care in England for different demographics of patients with a cardiovascular disease (CVD) risk factor. METHODS An existing ontology was used to capture PA-I and a new ontology was designed to cover several key concepts covering long-term conditions (LTC) indicating CVD risk factors. Readv2 and CTV3 codes were identified using the NHS Terms Browser. The Royal College of General Practitioners Research Surveillance Centre (RCGP RSC), a sentinel network of over 1800 primary care practices across England covering a population of over 15,000,000 registered patients, was used for data analyses covering a period from April 2017 to March 2021. To estimate the eligible population with a LTC that received a PA-I, the annual mean weekly rate/10,000 for a population with a given attribute (e.g. ethnicity) presenting to primary care with a LTC was used as a proxy for the eligible population for receiving a PA-I. The annual mean weekly rate/10,000 for a population with the same attribute (e.g. ethnicity) that received a PA-I was divided by proxy eligible population to determine the percentage of the population that received a PA-I that could have benefited from one. RESULTS Across all attributes and time periods (with the exception of the 18-39 group, 2017-2019) we see underuse of PA-I with a general trend of decreased use of PA-I after 2017. For the different attributes, the highest percentage of use is as follows: regions - London with ~40% use in 2019; ethnicities - ‘Other’ ethnicity with ~50% use in 2017; IMD - IMD1 (the most deprived quintile) with ~40% use in 2017; gender – females with ~35% use in 2017; age – 18-39 age group with ~100% use from 2017-2018. Additionally, there is marked variation that changes over time: ~2-fold greater use of PA-I in London compared to the Southeast in 2017, which increases to a nearly 4-fold increase by 2020; ~1.5-fold greater use of PA-I for the IMD-1 demographic compared to IMD5 in 2020; and ~3.5-fold greater use of PA-I for the 18-39 group compared to both the 40-64 and 65+ groups. CONCLUSIONS Our findings point to marked underuse and variation in PA-I use in primary care in England for individuals at risk of CVD. These results provide valuable insights that can inform policy and practice to improve population resilience while shifting away from a singular focus on supply-side constraints in healthcare systems.
- 7 October 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA novel ontological approach reveals underuse and variation in the use of physical activity interventions to address CVD risk factors in England primary care: Observational study (Preprint)
BACKGROUND In 2019, cardiovascular disease (CVD) accounted for 14% of total disability-adjusted life years and 30% of all deaths in England. Fast forwarding to 2020, many healthcare systems were on the verge of being overwhelmed by COVID-19, which disproportionately manifested as severe cases in populations affected by non-communicable diseases, most of which are CVD-risk factors. Physical activity interventions (PA-I) have been shown to play an important role in helping to address CVD risk factors and primary care has an essential role to play in supporting patients to improve their health through these types of interventions. OBJECTIVE In this manuscript, we explore the use of PA-I in primary care in England for different demographics of patients with a cardiovascular disease (CVD) risk factor. METHODS An existing ontology was used to capture PA-I and a new ontology was designed to cover several key concepts covering long-term conditions (LTC) indicating CVD risk factors. Readv2 and CTV3 codes were identified using the NHS Terms Browser. The Royal College of General Practitioners Research Surveillance Centre (RCGP RSC), a sentinel network of over 1800 primary care practices across England covering a population of over 15,000,000 registered patients, was used for data analyses covering a period from April 2017 to March 2021. To estimate the eligible population with a LTC that received a PA-I, the annual mean weekly rate/10,000 for a population with a given attribute (e.g. ethnicity) presenting to primary care with a LTC was used as a proxy for the eligible population for receiving a PA-I. The annual mean weekly rate/10,000 for a population with the same attribute (e.g. ethnicity) that received a PA-I was divided by proxy eligible population to determine the percentage of the population that received a PA-I that could have benefited from one. RESULTS Across all attributes and time periods (with the exception of the 18-39 group, 2017-2019) we see underuse of PA-I with a general trend of decreased use of PA-I after 2017. For the different attributes, the highest percentage of use is as follows: regions - London with ~40% use in 2019; ethnicities - ‘Other’ ethnicity with ~50% use in 2017; IMD - IMD1 (the most deprived quintile) with ~40% use in 2017; gender – females with ~35% use in 2017; age – 18-39 age group with ~100% use from 2017-2018. Additionally, there is marked variation that changes over time: ~2-fold greater use of PA-I in London compared to the Southeast in 2017, which increases to a nearly 4-fold increase by 2020; ~1.5-fold greater use of PA-I for the IMD-1 demographic compared to IMD5 in 2020; and ~3.5-fold greater use of PA-I for the 18-39 group compared to both the 40-64 and 65+ groups. CONCLUSIONS Our findings point to marked underuse and variation in PA-I use in primary care in England for individuals at risk of CVD. These results provide valuable insights that can inform policy and practice to improve population resilience while shifting away from a singular focus on supply-side constraints in healthcare systems.
- 9 April 2022
- Published by Elsevier in Journal of Infection
- Vol. 84 (6) , 814-824
Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network
- 9 April 2022
- Published by Elsevier in Journal of Infection
- Vol. 84 (6) , 814-824
Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network
- 3 January 2022
- Published by Elsevier in Journal of Infection
- Vol. 84 (5) , 675-683
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
- 3 January 2022
- Published by Elsevier in Journal of Infection
- Vol. 84 (5) , 675-683
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups